CN112007011A - PARP inhibitor pellet capsule and preparation process thereof - Google Patents

PARP inhibitor pellet capsule and preparation process thereof Download PDF

Info

Publication number
CN112007011A
CN112007011A CN201910468662.4A CN201910468662A CN112007011A CN 112007011 A CN112007011 A CN 112007011A CN 201910468662 A CN201910468662 A CN 201910468662A CN 112007011 A CN112007011 A CN 112007011A
Authority
CN
China
Prior art keywords
pellet
drug
active ingredient
pellets
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910468662.4A
Other languages
Chinese (zh)
Inventor
郭远静
王亦平
范文源
杜争鸣
仇罡
徐铄
吕会茹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiji Shenzhou Suzhou Biotechnology Co ltd
Original Assignee
Baiji Shenzhou Suzhou Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiji Shenzhou Suzhou Biotechnology Co ltd filed Critical Baiji Shenzhou Suzhou Biotechnology Co ltd
Priority to CN201910468662.4A priority Critical patent/CN112007011A/en
Publication of CN112007011A publication Critical patent/CN112007011A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a pellet capsule of PARP inhibitor and a preparation process thereof, wherein the pellet capsule comprises a pellet composition, and the composition comprises: (1) an active ingredient which is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a pharmaceutically acceptable salt thereof and a hydrate thereof; (2) a pellet core; (3) a binder; (4) optionally a coating material; and (5) optionally additional excipients.

Description

PARP inhibitor pellet capsule and preparation process thereof
Technical Field
The disclosure belongs to the field of medicines, and relates to a PARP inhibitor pellet capsule and a preparation method thereof, in particular to a pellet capsule of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacycloheptatriene [ def ] cyclopenta [ a ] fluorene-4 (5H) -one and pharmaceutically acceptable salts or hydrates thereof and a preparation method thereof.
Background
Adenosine diphosphate ribopolymerase (Poly (ADP-Ribose) Polymerase, PARP) is a class of proteases with important physiological functions. Is present in the nucleus of eukaryotic cells. The PARP family contains several PARP enzymes, of which PARP-1 is more important. In one aspect, PARP-1 is an abundant DNA notch sensitive protease that, upon binding to a DNA notch, activates PARP to cleave NAD + into nicotinamide and ADP-ribose and polymerize the latter to nuclear receptor proteins including histones, transcription factors, and PARP itself. Adenosine diphosphate ribose multimerization plays an important role in DNA repair and genomic stability. On the other hand, oxidative stress-induced PARP overactivation consumes NAD +, which in turn consumes ATP, accumulating to cause cell dysfunction or necrosis. This intracellular suicide mechanism is implicated in the pathological mechanisms of many diseases, such as stroke, myocardial infarction, diabetes-related cardiovascular dysfunction, shock, traumatic central nervous system injury, arthritis, inflammatory bowel disease, allergic encephalomyelitis and various other forms of inflammation. PARP has attracted widespread worldwide attention as a target for the treatment of malignancies. Olaparib (Olabprib) is the first PARP inhibitor worldwide and the drug is marketed in europe and the us.
WO2013/097225A1 discloses poly (ADP-ribosyl) transferase (PARPs) inhibitors and specifically compounds
Figure BDA0002080163410000011
I.e. (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def]Cyclopenta [ a ]]Fluoren-4 (5H) -one, an inhibitor of poly Adenosine Diphosphate (ADP) ribose polymerase (PARP), which is highly selective for PARP-1/2 and is effective in inhibiting proliferation of cell lines having the BRCA1/2 mutation or other HR deficiencies. WO2017/032289A1 discloses (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def]Cyclopenta [ a ]]A sesquihydrate of fluoren-4 (5H) -one having the structure:
Figure BDA0002080163410000012
the sesquihydrate has excellent chemical stability and is called pamiprarib. Preclinical studies have shown that Pamiparib has significant advantages in safety and efficacy over olaparib and other PARP inhibitors (such as Veliparib) that enter clinical stage III of the us FDA: has stronger DNA capture activity; pamiprarib is about 16-fold more active than olaparib in experiments with an in vitro xenograft model of BRCA variation; and has better PARP1/2 selectivity, and rodents have good tolerance to Pamiparib and about 10 times of therapeutic window; in addition, the drug has no CYP inhibitory activity and shows strong combined drug activity and excellent pharmacokinetic properties: has excellent DMPK property and remarkable brain permeability.
However, Pamiparib has poor flowability, and is difficult to directly fill and produce during the preparation process.
Therefore, there is a need to develop formulations that overcome the poor flowability of pamiprarib and are suitable for large-scale production.
Disclosure of Invention
In order to overcome the defects of the physical and chemical properties of the Pamiparib raw material medicine in the preparation of the preparation, the inventor makes a great deal of attempts in the development of the Pamiparib preparation, and finds that the Pamiparib is developed into a pellet preparation, so that the difficulty of the raw material medicine in the preparation is successfully reduced, the fluidity and the stability of the product are improved, the large-scale commercial production is possible, the transportation and the storage are convenient, the preparation process is simple and convenient, no special requirements are required on equipment, and the finally obtained finished product has good stability and is suitable for large-scale production. Furthermore, the inventors have unexpectedly found that mixing the prepared pellets with a certain amount of lubricant, such as talc, effectively reduces the electrostatic interaction between the pellets, thereby enabling industrial production of pellet formulations.
Therefore, the inventor of the invention successfully improves the flowability of the bulk drug powder after preparing the pamiprarib into the pellet; and mixing the pellets with lubricant such as pulvis Talci, to prevent electrostatic interaction between pellets, thereby facilitating capsule encapsulation.
On the basis, the inventor also discovers that the D of the bulk drug Pamiparib is discovered through a large amount of creative experimental research90Has a certain influence on the quality attributes of the final product, as an unexpected surprise, when D90Below 30 μm, the end product can be obtained with the desired quality attributes.
The invention relates to a PARP inhibitor pellet capsule and a preparation method thereof; and the use of such formulations for the treatment/prevention of diseases or disorders associated with PARP.
In a first aspect, the present invention relates to a PARP inhibitor pellet capsule comprising a pellet composition comprising: pellets comprising (1) a pellet core and optionally an additional excipient; (2) a drug-containing layer and (3) an optional protective layer; the drug-containing layer comprises (a) an active ingredient and (b) a binder; when the composition comprises a protective layer, the protective layer comprises (c) a coating material; the active ingredient is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -ketone, pharmaceutically acceptable salt and hydrate thereof.
In some embodiments, the present invention relates to a PARP inhibitor pellet capsule comprising a pellet composition comprising: pellets comprising (1) a pellet core and optionally an additional excipient; (2) a drug-containing layer; the drug-containing layer comprises (a) an active ingredient and (b) a binder; (3) an optional protective layer; the active ingredient is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -ketone, pharmaceutically acceptable salt and hydrate thereof.
In some embodiments, the present invention relates to a PARP inhibitor pellet capsule comprising a pellet composition comprising: pellets comprising (1) a pellet core and optionally an additional excipient; (2) a drug-containing layer and/or (3) a protective layer; the drug-containing layer comprises (a) an active ingredient and (b) a binder; the protective layer comprises (c) a coating material; the active ingredient is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -ketone, pharmaceutically acceptable salt and hydrate thereof.
Preferably, the pellet comprises (1) a pellet core, (2) a drug-containing layer and (3) an optional protective layer from inside to outside in sequence.
In the above pellet compositions, the optional additional excipients include, but are not limited to, fillers, lubricants and other conventionally used excipients. Preferably the additional excipient comprises one or more of a filler, a lubricant, more preferably the additional excipient comprises a lubricant.
In the pellet composition, the pellet core is a blank pellet core and is selected from one or more of a sucrose pellet core, a microcrystalline cellulose pellet core and a starch pellet core.
In the pellet composition, the pellet core accounts for 50-90 wt%, preferably 60-85 wt% (w/w) of the total weight of the pellet composition.
In the above pellet composition, the active ingredient is preferably (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one in the a-L crystal form or (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one in a hydrate form.
Preferably, the active ingredient is the C crystal form of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one.
The A-L crystal form can be prepared by referring to WO2017/032289A 1.
Preferably, the active ingredient is a sesquihydrate of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one having the following structure:
Figure BDA0002080163410000031
as an additional part of the invention, the inventors have found D of the active ingredient Pamiparib90Has an impact on the quality attributes of the final product.
Preferably, D of said active ingredient90Less than 100 μm, preferably D90Less than 50 μm.
As an unexpected surprise, when D90Less than 30 μm, the final product will achieve the desired final product content (above 99%), and therefore, most preferably, D of the active ingredient90Less than 30 μm. .
Preferably, the active ingredient is 5-50%, preferably 10-25%, and more preferably 10-20% (w/w) by weight of the total pellet composition.
Preferably, the active ingredient is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def [ ]]Cyclopenta [ a ]]C crystal form of fluorene-4 (5H) -ketone and particle size D90Less than 30 μm, the active ingredient is present in an amount of 10% to 25% (w/w), more preferably 10% to 20%, by weight of the total pellet composition.
Preferably, the active ingredient is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetra-hydro-)Aza cyclohepta [ def ]]Cyclopenta [ a ]]Sesquihydrate of fluorene-4 (5H) -one, particle size D90Less than 30 μm, the active ingredient is present in an amount of 10% to 25% (w/w), more preferably 10% to 20%, by weight of the total pellet composition.
In the pellet composition, the binder includes, but is not limited to, one or more of carbomer, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and povidone.
In the pellet composition, the binder accounts for 1-20 wt%, preferably 1-10 wt%, more preferably 3-8 wt%, and most preferably 3-6 wt% (w/w) of the total weight of the pellet composition.
Preferably, the binder is selected from hypromellose, hypromellose sodium and povidone.
More preferably, the binder is hypromellose and hypromellose sodium in an amount of 3-8% (w/w) based on the total weight of the pellet composition.
In the pellet composition, the coating material includes but is not limited to one or more of carbomer, sodium carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose and povidone.
In the pellet composition, the weight percentage of the coating material to the total weight of the pellet composition is 1-25%, preferably 1-10%, more preferably 1.5-8%, and most preferably 3-6% (w/w).
Preferably, the coating material is selected from hypromellose and hypromellose sodium.
More preferably, the coating material is hydroxypropyl methylcellulose and hydroxypropyl methylcellulose sodium which account for 1.5-8% (w/w) of the total weight of the pellet composition.
In the pellet composition, the lubricant includes, but is not limited to, one or more of calcium stearate, magnesium stearate, zinc stearate, stearic acid, sodium stearyl fumarate and talc.
In the pellet composition, the lubricant accounts for 0.1-5.0 wt%, preferably 0.1-2 wt% of the total weight of the pellet composition. More preferably 0.5% to 1.5% (w/w).
After the pamicarb is prepared into the pellet, the pellet successfully improves the flowability of the bulk drug powder, and the flowability is enough to meet the preparation requirement, so that no additional lubricant is needed to improve the flowability. Moreover, the inventor has discovered that electrostatic interaction is generated among the micro-pills, and the electrostatic interaction has certain influence on the filling of the capsule. In order to avoid the electrostatic problem, the inventor surprisingly found that the incorporation of certain lubricants, especially talc, into the pellets effectively reduces the electrostatic effect of the pellets, making it possible to mass-produce the formulation commercially. Thus, preferably, the lubricant is selected from talc.
Preferably, the lubricant is selected from 0.1-2 wt% of talcum powder based on the total weight of the pellet composition.
In a second aspect, the present invention also relates to a PARP inhibitor pellet capsule comprising a pellet composition comprising: (1) an active ingredient which is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a pharmaceutically acceptable salt and a hydrate thereof; (2) a pellet core; (3) a binder; (4) optionally a coating material; and (5) optionally additional excipients.
In some embodiments, the present invention relates to a PARP inhibitor pellet capsule comprising a pellet composition comprising: (1) an active ingredient which is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a pharmaceutically acceptable salt thereof and a hydrate thereof; (2) a pellet core; (3) a binder; and (4) optionally additional excipients.
In other embodiments, the present invention relates to a PARP inhibitor pellet capsule comprising a pellet composition comprising: (1) an active ingredient which is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a pharmaceutically acceptable salt thereof and a hydrate thereof; (2) a pellet core; (3) a binder; (4) coating materials; and (5) optionally additional excipients.
In the pellet composition, the types, contents and characteristics of the active ingredient, the pellet core, the binder, the coating material and the external excipient are defined as above.
In a third aspect, the present invention relates to a process for preparing a pellet composition.
A method of preparing a pellet composition, the method comprising the steps of:
1) dispersing the active ingredient in the adhesive solution to prepare a drug-containing suspension;
2) spraying the drug-containing suspension liquid obtained in the step 1) on the pellet core surface to form a drug-containing layer, and preparing a drug-loaded pellet;
3) preparing a coating material solution, spraying the coating material solution on the surface of the drug-loaded pellets to be used as a protective layer, and preparing protective layer pellets, wherein the step is optionally executed;
4) mixing the pellets obtained in the step 2) or the step 3) with an external excipient to prepare a total mixed pellet, wherein the step is optionally executed.
In some embodiments, the present invention relates to a method of preparing a pellet composition, the method comprising the steps of:
1) dispersing the active ingredient in the adhesive solution to prepare a drug-containing suspension;
2) spraying the drug-containing suspension liquid obtained in the step 1) on the pellet core surface to form a drug-containing layer, and preparing a drug-loaded pellet;
3) preparing a coating material solution, spraying the coating material solution on the surface of the drug-loaded pellets to be used as a protective layer, and preparing the protective layer pellets to obtain the pellet composition.
In some embodiments, the present invention relates to a method of preparing a pellet composition, the method comprising the steps of:
1) dispersing the active ingredient in the adhesive solution to prepare a drug-containing suspension;
2) spraying the drug-containing suspension liquid obtained in the step 1) on the pellet core surface to form a drug-containing layer, and preparing a drug-loaded pellet;
3) mixing the pellets obtained in the step 2) with an external excipient to prepare total mixed pellets, namely the pellet composition.
In some embodiments, the present invention relates to a method of preparing a pellet composition, the method comprising the steps of:
1) dispersing the active ingredient in the adhesive solution to prepare a drug-containing suspension;
2) spraying the drug-containing suspension liquid obtained in the step 1) on the pellet core surface to form a drug-containing layer, and preparing a drug-loaded pellet;
3) preparing a coating material solution, and spraying the coating material solution on the surface of the drug-loaded pellet as a protective layer to prepare a protective layer pellet;
4) mixing the pellets obtained in the step 3) with an external excipient to prepare total mixed pellets, thus obtaining the pellet composition.
In the pellet composition, the types, contents and characteristics of the active ingredient, the pellet core, the binder, the coating material and the external excipient are defined as above.
In a fourth aspect, the invention relates to a preparation method of a PARP inhibitor pellet capsule.
The capsule includes a capsule shell. The capsule shell is selected from gelatin hollow capsule shell and hypromellose hollow capsule shell, preferably gelatin hollow capsule shell.
Capsules of different sizes are filled according to the content of the raw material medicine in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredients contained in each capsule by the weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -ketone.
In a fifth aspect, the present invention relates to a method for treating and/or preventing diseases associated with PARP, said method using the pellet capsule of the present invention.
The invention also relates to application of an oral preparation prepared from the pellet capsule in preparing a medicament for treating and/or preventing PARP related diseases of mammals.
The diseases related to PARP in the present invention include but are not limited to: tumor angiogenesis; chronic inflammatory diseases such as rheumatoid arthritis, atherosclerosis; skin diseases such as psoriasis and scleroderma; diabetes-induced skin disease, diabetic retinopathy, retinopathy of prematurity, age-related degenerative stains, cancer, hemangioma, glioma, kaposi's sarcoma, ovarian cancer, breast cancer; lung cancer, including small cell lung cancer; pancreatic cancer, lymphoma, prostate cancer, colon cancer, and skin tumors, and their complications.
Among the mammals mentioned in the present application, humans are preferred.
The disease is preferably selected from BRCA1 and BRCA2 mutant tumors, such as BRCA1 and BRCA2 mutant breast, ovarian cancers and complications thereof.
The above-described methods of preventing or treating a disease may also be used in combination with any chemotherapy (e.g., Temozolomide (TMZ) and docetaxel (docetaxel)), biologic therapy, or radiation therapy.
Technical terms
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, the terms "comprises," "comprising," or any other variation thereof, mean that the compositions and methods described, etc., include the recited elements and do not exclude others.
The compositions of the present invention comprise a mixture of the active ingredient with other chemical ingredients.
Optionally, the term (i) as used herein means optionally with or without the addition of excipients, such as optional additional excipients means with or without additional excipients.
The lubricant comprises a conventionally used lubricant and/or a conventionally used glidant.
The invention provides a PARP inhibitor pellet capsule. The (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacycloheptatriene [ def ] cyclopenta [ a ] fluorene-4 (5H) -ketone active ingredient is prepared into the drug-carrying pellet, so that the insufficient physicochemical properties of the raw material drugs are successfully improved, the flowability and the stability of the product are improved, the large-scale commercial production is possible, the transportation and the storage are convenient, the preparation process is simple, and the final product and the intermediate product have good stability. In addition, the drug loading of the intermediate product micro-pill is high, different drug dosages can be adjusted according to clinical indications, and the micro-pill is convenient for patients to take.
The electrostatic effect of the micro-pill can be effectively reduced by mixing a certain amount of lubricant such as talcum powder in the micro-pill, so that the mass commercial production of the preparation becomes possible.
When D is present90Less than 30 μm, the final product will achieve the desired quality attributes of the final product.
Drawings
FIG. 1 is an electron microscope image of Pamiparib drug substance.
FIG. 2 is an electron micrograph of pellets of example 1
Detailed Description
The following examples may assist those skilled in the art in a more complete understanding of the present invention, but are not intended to limit the invention in any way. All the raw materials can be obtained commercially.
Example 1
Prescription of 100g pellet preparation:
80.50g of microcrystalline cellulose pellet core
A medicine-containing layer: pamiparib 12.08 g; povidone 4.02g
Protective layer: hydroxypropyl methylcellulose 2.90g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) povidone in the prescribed amount (4.02g) was weighed out to prepare a 5% strength binder solution, and 12.08g of pamiprarib was uniformly dispersed in the binder solution to prepare a drug-containing layer coating suspension.
2) Taking a prescribed amount of microcrystalline cellulose pellet cores, spraying the drug-containing layer coating suspension on the surfaces of the pellet cores to form drug-containing layers, and preparing the drug-loaded pellets. Taking the coating material hydroxypropyl methylcellulose with the prescription amount (2.90g) to prepare a coating material solution with the concentration of 5%, and spraying the coating material solution on the surface of the drug-loaded pellet as a protective layer to prepare the drug-loaded pellet containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
The attached figure 1 of the specification is an electron microscope image of a Pamiparib raw material drug, and the Pamiparib raw material drug contains crystal water, so that the Pamiparib raw material drug is easy to agglomerate, has poor flowability, is not beneficial to capsule filling and influences the technological large-scale production of the preparation. While the figure 2 in the specification is an electron microscope picture of the pellet of example 1, it can be seen that the pellet has a round shape, can be evenly spread under the field of view of the electron microscope, and has good fluidity. Can meet the filling requirement of the capsule.
Example 2
Prescription of 100g pellet preparation:
77.28g of sucrose pellet core
A medicine-containing layer: pamiparib 11.60 g; hydroxypropyl methylcellulose 7.73g
Protective layer: povidone 2.90g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a prescribed amount (7.73g) of hypromellose was weighed out to prepare a 5% strength binder solution, and 11.60g of pamiprarib was uniformly dispersed in the binder solution to prepare a drug-containing layer coating suspension.
2) And (3) taking a prescription amount of the sucrose pellet core, and spraying the drug-containing layer coating suspension on the surface of the pellet core to form a drug-containing layer, so as to prepare the drug-loaded pellet. Coating material povidone with the prescription amount (2.90g) is taken to prepare a coating material solution with the concentration of 5%, and the coating material solution is sprayed on the surface of the drug-loaded pellet to be used as a protective layer, so that the drug-loaded pellet containing the protective layer is prepared.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 3
Prescription of 100g pellet preparation:
80.50g of microcrystalline cellulose pellet core
A medicine-containing layer: pamiparib 12.08 g; hydroxypropyl methylcellulose 4.02g
Protective layer: hydroxypropyl methylcellulose 2.90g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a prescribed amount (4.02g) of hypromellose was weighed out to prepare a 5% strength binder solution, and 12.08g of pamiprarib was uniformly dispersed in the binder solution to prepare a drug-containing layer coating suspension.
2) Taking a prescribed amount of microcrystalline cellulose pellet cores, spraying the drug-containing layer coating suspension on the surfaces of the pellet cores to form drug-containing layers, and preparing the drug-loaded pellets. Taking the coating material hydroxypropyl methylcellulose with the prescription amount (2.90g) to prepare a coating material solution with the concentration of 5%, and spraying the coating material solution on the surface of the drug-loaded pellet as a protective layer to prepare the drug-loaded pellet containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 4
Prescription of 100g pellet preparation:
79.91g of microcrystalline cellulose pellet core
A medicine-containing layer: pamiparib 12.13 g; sodium carboxymethylcellulose 4.04g
Protective layer: sodium carboxymethylcellulose 2.42g
Talcum powder 1.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a prescribed amount (4.04g) of sodium carboxymethylcellulose was weighed out to prepare a 5% strength binder solution, and 12.13g of pamiprarib was uniformly dispersed in the binder solution to prepare a drug-containing layer coating suspension.
2) Taking a prescribed amount of microcrystalline cellulose pellet cores, spraying the drug-containing layer coating suspension on the surfaces of the pellet cores to form drug-containing layers, and preparing the drug-loaded pellets. Coating material sodium carboxymethylcellulose with the prescription amount of 2.42g is taken to prepare a coating material solution with the concentration of 5%, and the coating material solution is sprayed on the surface of the drug-loaded pellet to be used as a protective layer, so that the drug-loaded pellet containing the protective layer is prepared.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 5
Prescription of 100g pellet preparation:
80.50g of sucrose pellet core
A medicine-containing layer: pamiparib 12.08 g; sodium carboxymethylcellulose 4.02g
Protective layer: carbomer 2.90g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a prescribed amount (4.02g) of sodium carboxymethylcellulose was weighed out to prepare a 5% strength binder solution, and 12.08g of pamiprarib was uniformly dispersed in the binder solution to prepare a drug-containing layer coating suspension.
2) And (3) taking a prescription amount of the sucrose pellet core, and spraying the drug-containing layer coating suspension on the surface of the pellet core to form a drug-containing layer, so as to prepare the drug-loaded pellet. Taking the coating material carbomer with the prescription amount (2.90g) to prepare a coating material solution with the concentration of 5%, and spraying the coating material solution on the surface of the drug-loaded pellet as a protective layer to prepare the drug-loaded pellet containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 6
Prescription of 100g pellet preparation:
68.43g of microcrystalline cellulose pellet core
A medicine-containing layer: pamiparib 20.53 g; povidone 6.84g
Protective layer: sodium carboxymethylcellulose 3.70g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a drug-containing layer coating suspension was prepared by weighing a prescribed amount (6.84g) of povidone to prepare a 5% strength binder solution and uniformly dispersing 20.53g of pamiprarib in the binder solution.
2) Taking a prescribed amount of microcrystalline cellulose pellet cores, spraying the drug-containing layer coating suspension on the surfaces of the pellet cores to form drug-containing layers, and preparing the drug-loaded pellets. Coating material sodium carboxymethyl cellulose with the prescription amount (3.70g) is taken to prepare a coating material solution with the concentration of 5 percent, and the coating material solution is sprayed on the surface of the drug-carrying pellet to be used as a protective layer, so as to prepare the drug-carrying pellet containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 7
Prescription of 100g pellet preparation:
89.40g of microcrystalline cellulose pellet core
A medicine-containing layer: 5.16g of Pamiparib; hydroxypropyl cellulose 1.72g
Protective layer: hydroxypropyl methylcellulose 3.22g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a drug-containing layer coating suspension was prepared by weighing a prescribed amount (1.72g) of hydroxypropylcellulose to prepare a 5% strength binder solution, and uniformly dispersing 5.16g of pamiprarib in the binder solution.
2) Taking a prescribed amount of microcrystalline cellulose pellet cores, spraying the drug-containing layer coating suspension on the surfaces of the pellet cores to form drug-containing layers, and preparing the drug-loaded pellets. Taking the coating material hydroxypropyl methylcellulose with the prescription amount (3.22g) to prepare a coating material solution with the concentration of 5%, and spraying the coating material solution on the surface of the drug-loaded pellets to be used as a protective layer to prepare the drug-loaded pellets containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 8
Prescription of 100g pellet preparation:
sucrose pellet core 81.30g
A medicine-containing layer: pamiparib 12.19 g; hydroxypropyl methylcellulose 4.06g
Protective layer: sodium carboxymethylcellulose 1.95g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a prescribed amount (4.06g) of hypromellose was weighed out to prepare a 5% strength binder solution, and 12.19g of pamiprarib was uniformly dispersed in the binder solution to prepare a drug-containing layer coating suspension.
2) And (3) taking a prescription amount of the sucrose pellet core, and spraying the drug-containing layer coating suspension on the surface of the pellet core to form a drug-containing layer, so as to prepare the drug-loaded pellet. Coating material sodium carboxymethyl cellulose with the prescription amount (1.95g) is taken to prepare a coating material solution with the concentration of 5 percent, and the coating material solution is sprayed on the surface of the drug-carrying pellet to be used as a protective layer, so as to prepare the drug-carrying pellet containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 9
Prescription of 100g pellet preparation:
78.97g of microcrystalline cellulose pellet core
A medicine-containing layer: pamiparib 11.85 g; povidone 3.95g
Protective layer: hydroxypropyl methylcellulose 4.74g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
The preparation process comprises the following steps:
1) a drug-containing layer coating suspension was prepared by weighing a prescribed amount (3.95g) of povidone to prepare a 5% strength binder solution, and uniformly dispersing 11.85g of pamiprarib in the binder solution.
2) Taking a prescribed amount of microcrystalline cellulose pellet cores, spraying the drug-containing layer coating suspension on the surfaces of the pellet cores to form drug-containing layers, and preparing the drug-loaded pellets. Taking the coating material hydroxypropyl methylcellulose with the prescription amount (4.74g) to prepare a coating material solution with the concentration of 5%, and spraying the coating material solution on the surface of the drug-loaded pellets to be used as a protective layer to prepare the drug-loaded pellets containing the protective layer.
3) And (3) mixing the drug-loaded pellets (containing the protective layer) obtained in the step (a) with the prescribed amount of talcum powder to prepare the total mixed pellets.
4) And filling the total mixed pellets into capsules.
Capsules of different sizes are filled according to the content of the raw material drug in the pellets and the weight of the pellets, and the sizes include but are not limited to 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg and 100mg of active ingredient contained in each capsule based on the weight of the compound anhydrous substance.
Example 10 Effect of bulk drug particle size on the active ingredient content of Pamiparib pellet capsules
The inventor unexpectedly found D of Pamiparib drug substance in the process of formulation development90The value has certain influence on the content of the active ingredients in the final product of the pellet capsule preparation. The same recipe as in example 3 was used:
prescription of 100g pellet preparation:
80.50g of microcrystalline cellulose pellet core
A medicine-containing layer: pamiparib 12.08 g; povidone 4.02g
Protective layer: hydroxypropyl methylcellulose 2.90g
Talcum powder 0.50g
Wherein Pamiparib is calculated by the total weight of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluorene-4 (5H) -one sesquihydrate.
Experimental group 1: pamiparib D90＝7.87μm
Experimental group 2: pamiparib D90＝21.9μm
Experimental group 3: pamiparib D90＝35.6μm
Experimental group 4: pamiparib D90＝45.5μm
Capsules of 20mg content were prepared as described in example 3. The D90 was measured using a malvern laser particle sizer 3000 using a laser diffraction method.
Content determination: 225mg (allowable weighing range: 158-292mg) of the capsule content pellets are weighed, the content pellets are diluted by 250 times by using a diluent, mixed evenly, a 0.45 mu m PTFE needle filter is used, 3ml is discarded, filtrate is collected and detected at the wavelength of 297nm by using a UV method or is measured by using HPLC, and the content analysis result is as follows.
TABLE 1 content results for products prepared from bulk drug of different particle size
Experimental groups Content%
Experimental group 1 (D)90＝7.87μm) 99.2％
Experimental group 2 (D)90＝21.9μm) 99.9％
Experimental group 3 (D)90＝35.6μm) 91.5％
Experimental group 4 (D)90＝45.5μm) 90.6％
According to the experimental results, when D is90Below 30 μm, the final product has a higher content result.
The invention has been described in detail with respect to the general description, specific embodiments and experiments, and it is intended that all modifications and improvements made without departing from the spirit of the invention are within the scope of the invention as claimed.

Claims (10)

1. A PARP inhibitor pellet capsule comprising a pellet composition, said composition comprising:
(1) an active ingredient which is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a pharmaceutically acceptable salt thereof and a hydrate thereof; (2) a pellet core; (3) a binder; (4) optionally a coating material; and (5) optionally additional excipients.
2. The pellet capsule of claim 1, said additional excipient comprising one or more of a filler, a lubricant, more preferably said additional excipient comprising a lubricant.
3. The pellet capsule of claim 1 or 2, wherein the pellet core is a blank pellet core, and is selected from one or more of a sucrose pellet core, a microcrystalline cellulose pellet core and a starch pellet core; and/or
The weight percentage of the pellet core of the pellet accounts for 50-90 percent, preferably 60-85 percent (w/w) of the total weight of the pellet composition.
4. The pellet capsule of claim 1 or 2, wherein the active ingredient is in the form of a-L or a hydrate; preferably, the active ingredient is in form C; preferably, the active ingredient is a sesquihydrate having the following structure:
Figure FDA0002080163400000011
5. the pellet capsule of claim 4, wherein said active ingredient has a particle size D90Less than 100 μm, preferably D90Less than 50 μm, more preferably less than 30 μm; and/or the active ingredient is in microThe weight percentage of the total weight of the pellet composition is 5% to 50%, preferably 10% to 25%, and more preferably 10% to 20% (w/w).
6. The pellet capsule of claim 1 or 2, wherein said active ingredient is (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ™)]Cyclopenta [ a ]]C crystal form and/or sesquihydrate of fluorene-4 (5H) -ketone with particle diameter of D90Less than 30 μm, the active ingredient accounts for 10-25% of the total weight of the pellet composition.
7. The pellet capsule of claim 1 or 2, wherein the binder is selected from one or more of carbomer, sodium carboxymethylcellulose, hydroxypropylcellulose, hypromellose, sodium hypromellose, povidone; preferably, the binder is selected from hypromellose, hypromellose sodium, povidone; and/or the binder accounts for 1-20%, preferably 1-10%, more preferably 3-8%, and most preferably 3-6% (w/w) of the total weight of the pellet composition.
8. The pellet capsule of claim 1 or 2, wherein the coating material is selected from one or more of carbomer, sodium carboxymethylcellulose, hydroxypropylcellulose, hypromellose, sodium hypromellose, povidone; preferably hydroxypropyl methylcellulose and hydroxypropyl methylcellulose sodium; and/or the coating material accounts for 1-25% of the total weight of the pellet composition, preferably 1-10%, more preferably 1.5-8%, and most preferably 3-6% (w/w).
9. The pellet capsule of claim 3, wherein said lubricant comprises but is not limited to one or more of calcium stearate, magnesium stearate, zinc stearate, stearic acid, sodium stearyl fumarate, talc, preferably talc; and/or the lubricant accounts for 0.1-5.0% of the total weight of the pellet composition, and preferably 0.1-2%. More preferably 0.5% to 1.5% (w/w).
10. A process for the preparation of a pellet capsule according to any of claims 1-2, said process comprising the steps of:
1) dispersing the active ingredient in the adhesive solution to prepare a drug-containing suspension;
2) spraying the drug-containing suspension liquid obtained in the step 1) on the pellet core surface to form a drug-containing layer, and preparing a drug-loaded pellet;
3) preparing a coating material solution, spraying the coating material solution on the surface of the drug-loaded pellets to be used as a protective layer, and preparing protective layer pellets, wherein the step is optionally executed;
4) mixing the pellets obtained in the step 2) or the step 3) with an external excipient to prepare a total mixed pellet, wherein the step is optionally executed;
5) and (3) filling the pellets into capsules.
CN201910468662.4A 2019-05-31 2019-05-31 PARP inhibitor pellet capsule and preparation process thereof Pending CN112007011A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910468662.4A CN112007011A (en) 2019-05-31 2019-05-31 PARP inhibitor pellet capsule and preparation process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910468662.4A CN112007011A (en) 2019-05-31 2019-05-31 PARP inhibitor pellet capsule and preparation process thereof

Publications (1)

Publication Number Publication Date
CN112007011A true CN112007011A (en) 2020-12-01

Family

ID=73502137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910468662.4A Pending CN112007011A (en) 2019-05-31 2019-05-31 PARP inhibitor pellet capsule and preparation process thereof

Country Status (1)

Country Link
CN (1) CN112007011A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032464A (en) * 2007-04-01 2007-09-12 杨喜鸿 Combination containing rimonabant and polyvinyl pyrrolidone, solid dispersion and the preparing and medicine application thereof
CN106619567A (en) * 2017-01-02 2017-05-10 佛山市腾瑞医药科技有限公司 Trelagliptin succinate rapid-release pellet preparation and preparation method thereof
CN107922425A (en) * 2015-08-25 2018-04-17 百济神州有限公司 Method for preparing PARP inhibitor, crystal form and application thereof
WO2019090141A1 (en) * 2017-11-02 2019-05-09 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032464A (en) * 2007-04-01 2007-09-12 杨喜鸿 Combination containing rimonabant and polyvinyl pyrrolidone, solid dispersion and the preparing and medicine application thereof
CN107922425A (en) * 2015-08-25 2018-04-17 百济神州有限公司 Method for preparing PARP inhibitor, crystal form and application thereof
CN106619567A (en) * 2017-01-02 2017-05-10 佛山市腾瑞医药科技有限公司 Trelagliptin succinate rapid-release pellet preparation and preparation method thereof
WO2019090141A1 (en) * 2017-11-02 2019-05-09 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them

Similar Documents

Publication Publication Date Title
KR102006000B1 (en) Capsule formulation comprising montelukast or a pharmaceutically acceptable salt thereof, and levocetirizine or a pharmaceutically acceptable salt thereof
AU2011205164B2 (en) Compositions, suitable for oral administration, comprising a triazolo (4, 5-d) pyrimidin derivate
SI23290A (en) New forms of ivabradine hydrochloride
US20080045548A1 (en) Pharmaceutical Compositions
CN104363896A (en) Pharmaceutical composition of entecavir and process of manufacturing
CN105878250A (en) Aprepitant nano composition
CN103372014B (en) A kind of energy Fast Stripping, stable Vardenafil hydrochloric acid oral solid formulation and preparation method thereof
CN111184693B (en) RAF kinase inhibitor preparation and preparation method thereof
KR20130060220A (en) Enteric tablet
CN112007011A (en) PARP inhibitor pellet capsule and preparation process thereof
CN109963565B (en) Pharmaceutical composition and preparation method thereof
CN113438944A (en) Pellet preparation of PARP inhibitor and preparation process thereof
CN113412114A (en) ATR kinase inhibitor BAY1895344 for treating hyperproliferative diseases
EP2559431A1 (en) Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
JP2020029441A (en) Preparation containing dabigatran etexilate
KR20150079449A (en) Pharmaceutical composition containing clomipramine and its manufacturing method
JP2024511188A (en) Oral capsule of PARP inhibitor and method for its preparation
WO2007102038A1 (en) Ziprasidone formulations
KR101476096B1 (en) Pharmaceutical composition comprising celecoxib with improved solubility
KR20180112066A (en) A pharmaceutical composition comprising a pyrrolo-fused 6-membered heterocyclic compound
CN108853044A (en) A kind of Nifedipine sustained release tablets and preparation method thereof
EP2694039B1 (en) Solid preparation
CN114903867A (en) RAF kinase inhibitor capsule composition
CN106860868A (en) The pharmaceutical composition of husky class's class medicine and Lumbrokinase, preparation and its application
CN114845723A (en) Pharmaceutical composition comprising quinazoline derivative or salt thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination